Uptake of Adriamycin in tumour and surrounding brain tissue in patients with malignant gliomas
| Autor: | E. Knochenhauer, M. Lindquist, V. P. Collins, H. von Holst, L. Ehn, H. Blomgren, Carsten Peterson, G. Noren |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Adult
Male Pathology medicine.medical_specialty Metabolite medicine.medical_treatment Brain tissue Cell Line chemistry.chemical_compound Tumour tissue Glioma Tumor Cells Cultured polycyclic compounds medicine Humans Doxorubicin In patient Aged Chemotherapy Brain Neoplasms business.industry Brain Biological Transport Middle Aged medicine.disease chemistry Cell culture Injections Intravenous Female Surgery Neurology (clinical) business Cell Division medicine.drug |
| Zdroj: | Acta Neurochirurgica. 104:13-16 |
| ISSN: | 0942-0940 0001-6268 |
| DOI: | 10.1007/bf01842886 |
| Popis: | Eight patients with malignant gliomas verified on CT scan, received an intravenous injection of 50 mg of Adriamycin R, 24 hours prior to surgical removal of the tumour. Peroperatively, both tumour and surrounding tissue specimens were obtained for determination of the tissue concentrations of Adriamycin and its reduced metabolite Adriamycinol. It was found that Adriamycin could be detected in tumour tissue from all patients. The concentration varied between 0.9 and 4.6 nmol/g tissue. In contrast, Adriamycin could only be detected in surrounding brain tissue from one patient. In an in vitro study a human malignant glioma cell line (U-251 MG) was exposed to various concentrations of Adriamycin for 24 hours. It was found that an intracellular drug concentration above 30 nmol/g cells caused a concentration dependent inhibition of cell growth. Thus, it is likely that the poor effect of Adriamycin on patients with malignant gliomas is due to an ineffective drug accumulation in the tumour tissue. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink